Research programme: phosphatidylinositol 3 kinase inhibitors - Relay Therapeutics
Alternative Names: PI3Kα inhibitors - Relay TherapeuticsLatest Information Update: 29 Apr 2021
At a glance
- Originator Relay Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer